We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
ClinicalTrials.gov Menu

Transcranial Magnetic Stimulation (TMS) Treatment for Alzheimer Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01334450
Recruitment Status : Completed
First Posted : April 13, 2011
Last Update Posted : March 2, 2023
Information provided by:
Hadassah Medical Organization

Brief Summary:
Transcranial Magnetic Stimulation (TMS) for treatment of Alzheimer disease.

Condition or disease Intervention/treatment Phase
Alzheimer Disease Device: TMS , H2-coil Phase 2

Detailed Description:

Transcranial Magnetic Stimulation (TMS) for treatment of Alzheimer disease.

Alzheimer's disease (AD) is the leading cause of dementia and cognitive deteriorating in the advanced age. The current medical treatment of AD is mainly symptomatic and has many limitation. This main target of this study is to determine the safety and efficacy of transcranial magnetic stimulation (TMS) using novel coil design (H2) for stimulation of deep brain structures concomitantly with regular treatment in Alzheimer's disease (AD) patients. TMS acts by generating magnetic fields in the brain which simulate neuro-chemical changes and stimulate neuronal activity translating into increased secretion of growth factors such as brain derived neurotrophic factor (BDNF). Hence it is postulated that TMS will have a positive effect on the cognitive and behavioral symptoms of patients with AD and may ameliorated the progression of the disease. The treatment is non-invasive, with no significant side effects, and no need of hospitalization or anesthesia. The trial is phase IIb double blind study including 45 AD patients ages between 50 to 80 with mild or moderate AD (Mini Mental State Examination [MMSE] between 16 to 26) divided into 3 groups. All participants will receive standard medical therapy for AD. In addition, patients recruited for the study will receive 16 sessions of TMS with the H2 coil over 8 weeks. The first group will receive excitatory stimulation of 10 Hz over the prefrontal and parietal cortex, the second group will receive inhibitory stimulation of 1 Hz over similar brain areas and control patients will receive the same amount of Sham sessions. Patient will receive 3 treatments per week in the first 3 weeks and than 1 treatment per week for additional 4 weeks. Patients will be evaluated before the treatments, after 8 weeks of treatment and after another 8 weeks without treatment. The evaluations will include cognitive function according to ADAS-COG and MMSE, Activity of daily living (ADL) functions according to ADSC-ADL, behavioral function according to the Neuropsychiatric Inventory (NPI), depression according to the Cornell Scale for Depression in Dementia (CSDD), care giver satisfaction according to the RUD LITE scale and computerized cognitive evaluation according to the NEXING battery. We expect that the cognitive, behavioral and ADL functions will improve better in the study group as compared to the Sham treated group. From previous trial of TMS in neurological patients, although not in AD, we anticipate that adverse events rate will be similar between groups proving the safety of deep TMS treatment in patients with AD. In case our hypothesis will be proven, deep TMS treatment will be added as an important modality to the conventional therapy of AD patients.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 10 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Care Provider)
Primary Purpose: Treatment
Official Title: Deep-TMS for the Treatment of Alzheimer Disease Patients
Actual Study Start Date : June 2011
Actual Primary Completion Date : June 2012
Actual Study Completion Date : June 2012

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Active Comparator: High Frequency TMS to prefrontal cortex Device: TMS , H2-coil
Trans cranial magnetic stimulation with H2-coil
Other Name: Not relevant

Active Comparator: Low Frequency TMS to Prefrontal cortex Device: TMS , H2-coil
Trans cranial magnetic stimulation with H2-coil
Other Name: Not relevant

Sham Comparator: Sham TMS on Prefrontal Cortex Device: TMS , H2-coil
Trans cranial magnetic stimulation with H2-coil
Other Name: Not relevant

Primary Outcome Measures :
  1. cognitive functioning score by ADAS-COG [ Time Frame: 4 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   50 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Men and women aged 50-85.
  2. Diagnosed with Alzheimer's disease for at least half a year (by the DSM-IV criteria).
  3. Scored between 16-26 on the MMSE.
  4. Received drug therapy for their disease, with each treatment having been administered at an acceptable dosage for at least 5 weeks.
  5. Existence of a routine therapist for changes or adverse effects reports.
  6. Existence of Alzheimer diagnosis by CT or MRI tests.
  7. Answered in the negative to all questions in the pre-TMS treatment safety questionnaire.
  8. Gave their oral and written consent to participate in the trial.

Exclusion Criteria:

  1. An additional neurological disorder.
  2. Severe psychiatric disorder.
  3. Uncontrolled hypertension, beyond 170/110.
  4. History of epilepsy, seizure, or heat convulsion or History of epilepsy or seizure in first degree relatives.
  5. History of head injury or stroke.
  6. History of metal implants in the head (except dental fillings)or History of surgery entailing metallic implants or known history of any metallic particles in the eye, implanted cardiac pacemaker, cochlear implants, use of neurostimulators, or any medical pumps.
  7. History of migraines in the last six months.
  8. History of drug or alcohol abuse.
  9. Inadequate communication with examiner.
  10. Participation in another clinical study, either concurrent with this trial or in the 3 months preceding it.
  11. Inability to sign a consent form.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01334450

Layout table for location information
Hadassah Medical Center
Jerusalem District, Israel, 91120
Sponsors and Collaborators
Hadassah Medical Organization
Layout table for investigator information
Principal Investigator: Zeev Meiner, Dr. Hadassah Medical Organization
Layout table for additonal information
Responsible Party: Dr. Meiner Ze'ev, Hadassah Medical Center
ClinicalTrials.gov Identifier: NCT01334450    
Other Study ID Numbers: 0316
First Posted: April 13, 2011    Key Record Dates
Last Update Posted: March 2, 2023
Last Verified: April 2011
Keywords provided by Hadassah Medical Organization:
Improvement of ADAS-COG
Additional relevant MeSH terms:
Layout table for MeSH terms
Alzheimer Disease
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Neurodegenerative Diseases
Neurocognitive Disorders
Mental Disorders